Diffuse Large B-Cell Lymphoma Prognosis (R-IPI)
Determine prognosis in diffuse large B-cell lymphoma
The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy. Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma.
The revised International Prognostic Index (R-IPI) was developed to predict the outcome of individuals receiving rituximab with chemotherapy. The score is able to differentiate patients into three groups (very good, good, poor), all of who have survival >50% in the new era.
The original IPI was developed by Shipp et al.
The newer prognostic index was revised/developed by Sehn et al.